Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chinese ADC Developers Forge Domestic Alliances To Push R&D

Executive Summary

To date, nine major pairs of antibody and payload-linker platform makers based in China are making a concerted approach for ADC research and development, research by Scrip reveals.

You may also be interested in...



China 2024 Outlook: Biotech To Feel Ongoing Chill Despite Dealmaking Cheer

Biotech founders and executives in China are having to embrace continuing uncertainty around funding as the light at the end of the tunnel still appears a way off, but partnerships and alternative financing routes are providing some relief. 

China Biotech To Get More Chills Despite Dealmaking Cheers

Biotech founders and executives in China are embracing uncertainties as the light at the end of the tunnel is still not visible. 

Late To The Antibody-Drug Conjugate Party, But Will 2024 Be A Turning Point For India?

In 2024, Sun Pharma’s ADC candidate is expected to be in human trials, while CDMOs like Piramal Pharma Solutions and Aurigene are to operationalize significant new capacities. But can India compensate for a late start on the ADC journey by tapping low development costs and favorable policies, or is it too little with China far ahead in the race?

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC149518

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel